|Study Description:||The goal of this clinical research study is to learn about how vemurafenib may |
affect certain biomarkers in patients with PTC. Biomarkers are in the
blood/tissue and may be related to your reaction to the study drug. The safety
of this drug will also be studied.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer and cancer growth. By blocking this mutation, the drug may kill the
cancer cells with the mutation and/or stop the tumor from growing.